1. To investigate the effect of fenofibrate on cachexia in patients with NSCLC
This is a retrospective study being done in collaboration with members of Memorial Sloan Kettering's Division of Endocrinology and Department of Radiology. We are reviewing the charts of patients with NSCLC being treated with fenofibrate, and will investigate the change in skeletal muscle mass over time using measures from standard of care computed tomography imaging in patients on fenofibrate in comparison to untreated NSCLC patients.
2. To confirm the presence of hypoketonemia in patients with NSCLC
In collaboration with members of the Division of Thoracic Surgery, Medical Oncology, and the Meyer Cancer Center, we plan to collect serum and skeletal muscle tissue from patients with NSCLC-associated cachexia. We will conduct targeted metabolomic profiling on the serum to correlate the abundance of serum ketones with computed tomography measures of skeletal muscle mass, markers of skeletal muscle histone acetylation, mitochondrial content, and fatty acid oxidation.
3. To Evaluate the Metabolomic and Tissue Effects of a Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients
This is a feasibility study done in collaboration with Memorial Sloan Kettering Cancer Centerand the Clinical Translational Science Center at Weill Cornell. Here we are studying the effects of the classic ketogenic diet on women with endometrial cancer in the neoadjuvant setting.
4. To evaluate the PI3K Inhibitor, Copanlisib, in Combination with a Ketogenic Diet in the Treatment of Patients with Relapsed or Refractory Lymphoma or Endometrial Cancer
This is a pilot phase Ib/II study done in collaboration with Columbia University Medical Center, Memorial Sloan Kettering Cancer Center, and the Clinical Translational Science Center at Weill Cornell. Here we are testing if a PI3K inhibitor improves outcomes when paired with a classic ketogenic diet.